Journal

Blood Advances

2473-9529 · American Society of Hematology

73 verified public works

Browse all journals →

The roots run deep in therapy-related myeloid neoplasms

2026 · 0 citations

CC-486 plus venetoclax: another step toward oral AML therapy

2026 · 0 citations

Yu H, Schroeder JA, Mattson JG, Gao C, and Shi Q. Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice. Blood Adv. 2026;10(6):1883-1896.

2026 · 0 citations

Beyond hemolysis: redefining pediatric AIHA

2026 · 0 citations

Thrombophilia testing: does it truly affect risk?

2026 · 0 citations

New views on VUSs in RUNX1-FPD

2026 · 0 citations

Democratizing cancer risk testing in children before alloHCT

2026 · 0 citations

Real-world investigation of germ line predisposition to myelodysplastic syndromes

2026 · 0 citations

Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML

2026 · 0 citations

A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia

2026 · 0 citations

Of mice and FVIIIa mimetics: new hemophilia A models for in vivo evaluation

2026 · 0 citations

Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase

2026 · 0 citations

Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia

2026 · 0 citations

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial

2026 · 0 citations

Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826)

2026 · 0 citations

Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations

2026 · 0 citations

Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma

2026 · 0 citations

Comutation of asxl1 and IDH2 R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish

2026 · 0 citations

JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation

2026 · 0 citations

Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin

2026 · 0 citations

Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial

2026 · 0 citations

Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis

2026 · 0 citations

Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms

2026 · 0 citations

Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States

2026 · 0 citations

MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL

2026 · 0 citations

Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma

2026 · 0 citations

Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis

2026 · 0 citations

HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL

2026 · 0 citations

Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights

2026 · 0 citations

Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP

2026 · 0 citations